2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2013
Bile duct involvement portends poor prognosis in resected gallbladder carcinoma.
Eil R, Hansen P, Cassera M, Orloff S, Sheppard B, Diggs B, Billingsley K. Bile duct involvement portends poor prognosis in resected gallbladder carcinoma. Gastrointestinal Cancer Research : GCR 2013, 6: 101-5. PMID: 24147157, PMCID: PMC3782874.Peer-Reviewed Original ResearchDisease-specific survivalDisease-free survivalBile duct involvementGallbladder cancerDuct involvementMedian disease-free survivalResection of GBCResectable gallbladder cancerSubset of patientsLog-rank analysisAdjuvant therapyLN involvementPrognostic factorsCox regressionPoor prognosisRetrospective studyUnfavorable prognosisUnivariate analysisGallbladder carcinomaUnivariate associationsStudy populationHigh riskIntraoperative methodHigh mortalityMultivariate analysis
2011
Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases
Hammill C, Billingsley K, Cassera M, Wolf R, Ujiki M, Hansen P. Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases. Annals Of Surgical Oncology 2011, 18: 1947-1954. PMID: 21399885, DOI: 10.1245/s10434-010-1535-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationCohort StudiesColorectal NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansLaparoscopyLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareProspective StudiesRetrospective StudiesSurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsColorectal liver metastasesLaparoscopic radiofrequency ablationResectable colorectal liver metastasesRadiofrequency ablationResectable groupHepatic resectionLiver metastasesUnresectable groupMedian disease-free survivalComparable long-term survivalOutcomes of patientsDisease-free survivalKaplan-Meier methodLog-rank testLong-term survivalDiagnostic imaging studiesFavorable morbidityCRLM patientsPostoperative mortalityUnresectable diseaseMajor complicationsTumor numberResultsA totalSurgical oncologistsOutcome data